Osteoporosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 50 or older who have been diagnosed with postmenopausal osteoporosis (with or without a fracture) and for whom a doctor has decided to start treatment with bone-strengthening medications, such as bisphosphonates, raloxifene, teriparatide, denosumab, or romosozumab, taken by mouth or injection as part of their normal care.
- People who are willing and able to give written consent to take part in a research study.
- People who are enrolled in a French Social Security scheme (confirm with trial site).
Who may not be able to join:
- People who have severe chronic kidney disease, specifically where the kidneys are filtering at less than 30 mL per minute as measured by a standard kidney function calculation.
- People whose past or current medical or surgical history is considered by the trial doctor to be incompatible with taking part in the trial.
- People who are under legal protection or whose freedom is restricted by law (for example, those under guardianship or in custody).
- People who do not wish to participate in the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marie-Eva Pickering, University Hospital, Clermont-Ferrand
Phone: +33473754963
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment; Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment; Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment; Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment; Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.